UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 1825, 2025

TUHURA BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

Nevada	001-37823	99-0360497
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State or Other Jurisdictionof Incorporation)	(Commission File Number)	(IRS EmployerIdentification No.)

10500 University Center Dr., Suite 110 ~~Tampa, Florida 33612 (Address of Principal Executive Offices, including zip code)~~

Tampa, Florida 33612

(Address of Principal Executive Offices, including zip code)

Registrant’s Telephone Number, Including Area Code: (813) 875-6600

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~Trading Symbol~~TradingSymbol(s)		Name of each ~~exchange~~exchangeon on which registered
Common Stock, $0.001 par value per share		HURA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8 7.01. ~~Other~~Regulation ~~Events.~~FD Disclosure.

~~Updated~~On ~~Pro~~November 22, ~~Forma~~2025, ~~Financial~~TuHURA ~~Statements~~Biosciences, Inc.’s (the “Company”) Registration Statement on Form S-3 (File No. 333-291239) (the “Shelf Registration Statement”) initially filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025, became effective in accordance with the provisions of Section 8(a) of the Securities Act of 1933, as amended (the “Securities Act”).

As previously disclosed, on June 302, 2025, ~~TuHURA~~the ~~Biosciences,~~Company ~~Inc.,~~completed aits ~~Nevada~~private ~~corporation~~placement ~~(“TuHURA”),~~with ~~completed~~investors ~~its~~of ~~previously~~shares ~~announced~~of ~~acquisition~~the ~~contemplated~~Company’s bycommon ~~the~~stock ~~Agreement~~ and ~~Plan~~warrants ofto ~~Merger,~~purchase ~~dated~~common ~~December 11~~stock, ~~2024,~~and asin ~~amended~~connection bytherewith, ~~that~~the ~~certain~~Company ~~First~~registered ~~Amendment~~the tooffer ~~Agreement~~ and ~~Plan~~sale of ~~Merger,~~up ~~dated~~to ~~May 5~~9,321,545 ~~2025~~shares ~~(as~~of ~~amended,~~the Company’s common stock (the “~~Merger Agreement~~Shares”), bycomprising ~~and~~up ~~among~~to ~~TuHURA~~4, ~~Hura Merger Sub I~~570,629 ~~Inc.,~~shares aof ~~Delaware~~common ~~corporation~~stock and a4,750,916 ~~direct~~shares ~~wholly-owned subsidiary~~ of ~~TuHURA~~common ~~(“Merger~~stock ~~Sub~~issuable ~~I”),~~upon ~~Hura~~the ~~Merger~~exercise ~~Sub~~of ~~II,~~warrants ~~LLC,~~pursuant to a ~~Delaware~~Registration ~~limited~~Statement ~~liability~~on ~~company~~Form ~~and~~S-1 ~~direct~~(File ~~wholly~~No. 333-~~owned~~289532) ~~subsidiary~~initially offiled ~~TuHURA~~with ~~(“Merger~~the ~~Sub~~SEC ~~II”),~~on ~~Kineta~~August 12, ~~Inc.~~2025, ~~a Delaware corporation (“Kineta”),~~ and ~~Craig~~declared ~~Philips,~~effective ~~solely~~by inthe ~~his~~SEC ~~capacity~~on ~~as the representative~~September 26, ~~agent~~2025 ~~and attorney-in-fact of~~ (the ~~stockholders~~“Resale ofRegistration ~~Kineta~~Statement”). Pursuant to ~~the~~Section 415(a)(6) ~~terms~~ of the ~~Merger~~Securities ~~Agreement~~Act, ~~among~~the ~~other~~offering ~~things,~~of ~~(a) Merger~~the ~~Sub~~Shares Ihas ~~merged~~been ~~with~~deemed ~~and~~to ~~into~~continue ~~Kineta~~as ~~(the~~part ~~“First~~of ~~Merger”),~~the ~~with~~offering ~~Kineta~~covered ~~being~~by the ~~surviving~~Shelf ~~corporation~~Registration ofStatement and the ~~First~~Resale ~~Merger,~~Registration ~~also~~Statement ~~known~~deemed terminated as of the ~~“Surviving~~effective ~~Entity”~~date ~~and~~of ~~(b) immediately~~the ~~following~~Shelf ~~the~~Registration ~~First~~Statement. ~~Merger~~As such, the ~~Surviving~~offering ~~Entity~~of ~~merged~~the ~~with~~same ~~and~~Shares ~~into~~by ~~Merger Sub II (~~the ~~“Second~~selling ~~Merger”,~~securityholders ~~and~~named ~~together~~in ~~with~~ the ~~First~~Resale ~~Merger,~~Registration ~~the~~Statement ~~“Mergers”),~~will ~~with~~now ~~Merger~~be ~~Sub~~made IIfrom ~~being~~time ~~the~~to ~~surviving~~time ~~company~~pursuant ofto the ~~Second~~Shelf ~~Merger~~Registration Statement.

~~TuHURA~~The isinformation ~~providing~~under asItem ~~Exhibit 99~~7.101 toof this Current Report on Form 8-K ~~(the~~is ~~“Report”)~~intended ~~its~~to ~~unaudited~~be ~~pro~~furnished ~~forma~~and ~~condensed~~shall ~~combined~~not ~~statement~~be ofdeemed ~~operations~~“filed” for purposes of Section 18 of the ~~nine~~Securities ~~months~~Exchange ~~ended~~Act ~~September 30~~of 1934, ~~2025~~as amended (the “Exchange Act”), ~~and~~or otherwise subject to the ~~year~~liabilities ~~ended~~of ~~December 31~~that section, ~~2024~~nor onshall ait ~~pro~~be ~~forma~~deemed ~~basis~~incorporated asby ifreference ~~the~~in ~~Mergers~~any ~~and~~filing ~~TuHURA’s~~under ~~previously~~the ~~announced~~Securities ~~reverse~~Act ~~merger~~of ~~with~~1933, ~~Kintara~~as ~~Therapeutics~~amended, ~~Inc.~~or ~~that~~the ~~closed~~Exchange ~~on October 18~~Act, ~~2024~~except ~~had~~as ~~been~~expressly ~~consummated~~set onforth ~~January 1,~~by ~~2024~~specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(b) Pro forma financial information

The following unaudited pro forma financial information of TuHURA is attached as Exhibit 99.1 to this Report and incorporated by reference herein:

• Unaudited Pro Forma Condensed Combined Statements of Operations for TuHURA for the nine months ended September 30, 2025.

• Unaudited Pro Forma Condensed Combined Statement of Operations for TuHURA for the year ended December 31, 2024.

• Notes to Unaudited Pro Forma Condensed Consolidated Financial Statements.

(d) Exhibits

Exhibit No
99.1		Unaudited Pro Forma Condensed Combined Statements of Operation of TuHURA Biosciences, Inc. for the nine months ended September 30, 2025 and for the year ended December 31, 2024
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

Forward-Looking Statements

This Current Report on Form 8-K includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are not guarantees of future performance and that TuHURA’s actual results may differ materially from those set forth in the forward-looking statements. All of these forward-looking statements are subject to risks and uncertainties that may change at any time. Factors that could cause TuHURA’s actual expectations to differ materially from these forward-looking statements and include the factors under the heading “Risk Factors” set forth in TuHURA’s Annual Report on Form 10-K, as supplemented by TuHURA’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Such filings are available on our website or at www.sec.gov. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof. TuHURA undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TUHURA BIOSCIENCES, INC.

Date: November 18, 2025

/s/ Dan Dearborn

Date: November 25, 2025

/s/ Dan Dearborn

Name: Dan Dearborn Title: Chief Financial Officer

Filing Compare · TuHURA Biosciences, Inc./NV